Adebrelimab and Chemoradiotherapy in High-risk LANPC

This study tests whether adding an immunotherapy drug called adebrelimab to the standard chemotherapy-plus-radiation treatment improves outcomes for people with high-risk, locally advanced nasopharyngeal carcinoma (a type of head and neck cancer). **You may be eligible if...** - You have a confirmed diagnosis of nasopharyngeal carcinoma (a type of cancer at the back of the nose/throat) - Your cancer is staged as IVA or T3N2M0 (meaning locally advanced but not spread to distant organs) - You are in good general health (ECOG performance status 0 or 1) - Your blood counts, liver function, and kidney function are within acceptable ranges - Women of childbearing potential must agree to use effective contraception **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have serious organ dysfunction (liver, kidney, heart, or bone marrow problems) - You are pregnant or breastfeeding - You have active autoimmune disease Talk to your doctor to see if this trial is right for you.